Tenet Healthcare (NYSE:THC) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Tenet Healthcare (NYSE:THC) from a buy rating to a strong-buy rating in a report released on Monday morning.

A number of other equities analysts have also issued reports on the company. Robert W. Baird increased their price target on Tenet Healthcare from $210.00 to $280.00 and gave the company a “neutral” rating in a research note on Tuesday, July 28th. Piper Sandler set a $308.00 price objective on Tenet Healthcare in a report on Monday, July 27th. Royal Bank Of Canada lifted their target price on Tenet Healthcare from $236.00 to $283.00 and gave the stock an “outperform” rating in a report on Monday, July 27th. Guggenheim boosted their price target on shares of Tenet Healthcare from $242.00 to $283.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Tenet Healthcare in a research report on Monday, July 27th. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $271.00.

Tenet Healthcare Stock Down 2.1%

Tenet Healthcare stock opened at $249.53 on Monday. The company’s 50-day moving average price is $193.61 and its two-hundred day moving average price is $199.70. The stock has a market cap of $21.49 billion, a price-to-earnings ratio of 9.62, a PEG ratio of 0.97 and a beta of 1.23. Tenet Healthcare has a 52 week low of $156.71 and a 52 week high of $262.68. The company has a current ratio of 1.41, a quick ratio of 1.35 and a debt-to-equity ratio of 2.00.

Tenet Healthcare (NYSE:THC) last posted its quarterly earnings data on Thursday, July 23rd. The company reported $6.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.26 by $1.86. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The business had revenue of $6.04 billion during the quarter, compared to analysts’ expectations of $5.43 billion. During the same period last year, the firm posted $4.02 earnings per share. The business’s revenue was up 6.8% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. On average, analysts expect that Tenet Healthcare will post 21.09 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director J Robert Kerrey sold 5,638 shares of Tenet Healthcare stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $174.52, for a total transaction of $983,943.76. Following the transaction, the director owned 16,804 shares in the company, valued at approximately $2,932,634.08. The trade was a 25.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Paola M. Arbour sold 10,878 shares of the company’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $243.90, for a total value of $2,653,144.20. Following the transaction, the executive vice president directly owned 18,413 shares in the company, valued at $4,490,930.70. The trade was a 37.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 33,353 shares of company stock worth $7,683,517 in the last quarter. Corporate insiders own 0.97% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in THC. Price T Rowe Associates Inc. MD boosted its stake in shares of Tenet Healthcare by 1.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,490,350 shares of the company’s stock valued at $1,488,484,000 after buying an additional 119,809 shares during the period. Boston Partners boosted its position in Tenet Healthcare by 15.7% during the fourth quarter. Boston Partners now owns 3,642,136 shares of the company’s stock valued at $723,804,000 after purchasing an additional 494,581 shares during the last quarter. AQR Capital Management LLC grew its stake in Tenet Healthcare by 20.3% in the fourth quarter. AQR Capital Management LLC now owns 2,256,539 shares of the company’s stock valued at $448,419,000 after purchasing an additional 380,116 shares in the last quarter. Ameriprise Financial Inc. increased its position in Tenet Healthcare by 8.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,119,423 shares of the company’s stock worth $373,020,000 after purchasing an additional 157,109 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Tenet Healthcare during the 4th quarter worth about $248,494,000. Institutional investors and hedge funds own 95.44% of the company’s stock.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.